Our findings suggested that strategies aimed at regulating miR-25-3p levels, its transmission, or the inhibition of the PI3K-AKT-mTOR pathway’s activation may interfere with the immunosuppressive milieu, offering an innovative strategy for glioma immunotherapy. This evidence concerns the gene MTOR and central nervous system cancer.